Accessibility Menu
RegeneRx Biopharmaceuticals logo

RegeneRx Biopharmaceuticals(OTC) RGRX

Market Cap$1.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1987)-100%
5 Year-100%
1 Year+450%
1 Month+83%
$0.00
+0.00%
+0.00Today
RegeneRx Biopharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-02
RegeneRx Biopharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+57.14%USD 0.002026-08-25
1 month+83.33%USD 0.002026-07-14
3 month+83.33%USD 0.002026-05-27
Year to date+266.67%USD 0.002025-12-31
1 year+450%USD 0.002025-08-28
3 year-99.95%USD 2.122023-09-01
5 year-99.99%USD 21.982021-09-03
Since inception-100%USD 1,725.001987-06-16

RegeneRx Biopharmaceuticals Financials at a Glance

Market Cap

$1.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$76.76K

Net Income (TTM)

-$1.69M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

483.29 (High)

Price

$0.00

Volume

2

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.17

Estimated Earnings Date

N/A

RGRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About RegeneRx Biopharmaceuticals

RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm focused on developing therapeutic peptides, particularly thymosin beta 4, aimed at tissue protection, repair, and regeneration. The company’s innovative pipeline includes RGN-259, RGN-352, and RGN-137, targeting various medical conditions.

Products and Services
  • RGN-259: An ophthalmic solution for corneal tissue restoration
  • RGN-352: An injectable formulation for cardiovascular and nervous system disorders
  • RGN-137: A topical gel for accelerating skin wound healing
Growth Outlook
  • Strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. enhance market reach
  • Focus on innovative therapies positions the company for potential market expansion
  • Continued investment in R&D may lead to breakthrough treatments in biotechnology
Financial Highlights
  • Q1 2023 revenue of 19,190 reflects consistent performance over recent quarters
  • Net income for Q1 2023 was -385,000, indicating ongoing operational challenges
  • Cash and cash equivalents decreased to 101,557, highlighting liquidity concerns
RegeneRx Biopharmaceuticals, Inc. operates in a competitive biotechnology landscape, focusing on innovative therapeutic solutions. The company’s commitment to developing advanced treatments for tissue repair and regeneration is underscored by its strategic partnerships and ongoing research initiatives. Despite facing financial challenges, including negative net income and liquidity concerns, the consistent revenue generation indicates a stable operational foundation. Investors may find the company's focus on innovative therapies and strategic alliances appealing as it seeks to navigate the complexities of the biotechnology sector.
AI Generated • Aug 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

J. J. Finkelstein

Website

www.regenerx.com

Headquarters

Rockville, MD 20850, US

RGRX Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-1826.45%

Net Income Margin

-2249.84%

Return on Equity

60.86%

Return on Capital

N/A

Return on Assets

-451.88%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.50M

Volume

2

Avg. Volume

47.547

Financials (TTM)

Gross Profit

$76.76K

Operating Income

-$1.36M

EBITDA

-$304.84K

Operating Cash Flow

-$823.75K

Capital Expenditure

$0.00

Free Cash Flow

-$823.75K

Cash & ST Invst.

$101.56K

Total Debt

$1.49M

RegeneRx Biopharmaceuticals Performance Analysis

RegeneRx Biopharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 76,761N/A
20222022-12-31USD 76,7610.0%
RegeneRx Biopharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-06-30N/A
Q32022-09-30-0.0%
Q42022-12-31N/A
Q12023-03-31N/A
RegeneRx Biopharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -1.15N/A
20222022-12-31USD -1.204.3%
RegeneRx Biopharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-06-30-26.7%
Q32022-09-3031.6%
Q42022-12-31-3.8%
Q12023-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2023YOY CHG

Revenue

$19.19K

-0.0%

Gross Profit

$19.19K

-0.0%

Gross Margin

100.00%

N/A

Market Cap

$1.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$800.00

N/A

Employees

2

N/A

Net Income

-$385.00K

+9.2%

EBITDA

-$304.99K

-191718.9%

Quarterly Fundamentals

Name
Q1 2023YOY CHG

Total Cash

$101.56K

-89.0%

Total Debt

$1.49M

+23.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$279.69K

-76.6%

Short Term Debt

$1.21M

+7360.4%

Return on Assets

-4.52%

N/A

Return on Invested Capital

8.18%

N/A

Free Cash Flow

-$189.33K

+38.2%

Operating Cash Flow

-$189.33K

+38.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HMGNHemagen Diagnostics, Inc.
$0.00+0.00%
FFNTF4Front Ventures Corp.
$0.00+0.00%
DRWNQuantum Medical Transport, Inc.
$0.00+0.00%
NBIONascent Biotech, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About RGRX

What is the current price of RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals is trading at $0.00 per share.

What is the 52-week range for RegeneRx Biopharmaceuticals?

Over the past 52 weeks, RegeneRx Biopharmaceuticals has traded between $0.00 and $0.17.

How much debt does RegeneRx Biopharmaceuticals have?

As of the most recent reporting period, RegeneRx Biopharmaceuticals reported total debt of $1.45M.

How much cash does RegeneRx Biopharmaceuticals have on hand?

RegeneRx Biopharmaceuticals reported $290.89K in cash and cash equivalents in its most recent financial results.

What is RegeneRx Biopharmaceuticals’s dividend yield?

RegeneRx Biopharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services